@article{b3f157dd126d48b6b8619ccfd771f0ed,
title = "IncobotulinumtoxinA for the treatment of lower-limb spasticity in children and adolescents with cerebral palsy: A phase 3 study",
abstract = "PURPOSE: Investigate the efficacy and safety of multipattern incobotulinumtoxinA injections in children/adolescents with lower-limb cerebral palsy (CP)-related spasticity.",
keywords = "Botulinum toxin, all movement disorders, all paediatric, cerebral palsy, incobotulinum, spasticity",
author = "Florian Heinen and Petr Kanovsk{\'y} and Schroeder, {A. Sebastian} and Chambers, {Henry G.} and Edward Dabrowski and Geister, {Thorin L.} and Angelika Hanschmann and Martinez-Torres, {Francisco J.} and Irena Pulte and Marta Banach and Deborah Gaebler-Spira",
note = "Funding Information: Florian Heinen has received speaker{\textquoteright}s honoraria from Allergan plc, Desitin, Ipsen Biopharmaceuticals, Merz Pharmaceuticals, and Novartis and unrestricted educational grants from Allergan and Merz Pharmaceuticals. Petr Kanˇovsk{\'y} has received speaker{\textquoteright}s honoraria from Desitin, Ipsen Biopharmaceuticals, Merz Pharmaceuticals, and Medtronic. A. Sebastian Schroeder has received speaker{\textquoteright}s honoraria from and participated in advisory boards for Allergan plc, Ipsen Biopharmaceu-ticals, and Merz Pharmaceuticals. Henry G. Chambers serves as a consultant for Orthopediatrics Corp and Allergan Corporation. Edward Dabrowski has participated in an advisory board and speaker bureau for Ipsen Bio-pharmaceuticals. Thorin L. Geister is an employee of Merz Pharmaceuticals GmbH. Angelika Hanschmann is an employee of Merz Pharmaceuticals GmbH. Francisco J. Martinez-Torres is a former employee of Merz North America LLC. Irena Pulte is an employee of Merz Pharmaceuticals GmbH. Marta Banach has served as a consultant and speaker and participated in an advisory board for Merz Pharmaceuticals and has served as a speaker for Allergan, Ipsen, and Kedrion. Deborah Gaebler-Spira has served as a consultant for Teva and Kashiva. Funding Information: The authors wish to thank all study subjects and investigators. They would like to acknowledge Hanna Dersch and Annette Lehn for statistical support and Amy Rothman Schonfeld and Caroline Spencer (Rx Communications, Mold, UK) for medical writing assistance with the preparation of this manuscript, funded by Merz Pharmaceuticals GmbH. This study was supported by Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany. Publisher Copyright: {\textcopyright}? 2 randomized (1:1:2) to incobotulinumtoxinA (4, 12, 16 U/kg, maximum 100, 300, 400 U, respectively) for two 12-To 36-week injection cycles. ",
year = "2021",
doi = "10.3233/PRM-210040",
language = "English (US)",
volume = "14",
pages = "183--197",
journal = "Journal of Pediatric Rehabilitation Medicine",
issn = "1874-5393",
publisher = "IOS Press",
number = "2",
}